Immune checkpoint inhibitor-related acral vasculitis

被引:34
作者
Comont, Thibault [1 ]
Sibaud, Vincent [2 ]
Mourey, Loic [3 ]
Cougoul, Pierre [1 ]
Beyne-Rauzy, Odile [1 ]
机构
[1] CHU Toulouse, Purpan Inst Univ Canc Toulouse Oncopole, Serv Med Interne, 1 Av Joliot Curie, F-31100 Toulouse, France
[2] Inst Univ Canc Toulouse Oncopole, Serv Oncodermatol, Toulouse, France
[3] Inst Univ Canc Toulouse Oncopole, Serv Oncol Med, Toulouse, France
关键词
Immune check point inhibitors; Immune-related adverse events; Vasculitis;
D O I
10.1186/s40425-018-0443-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Commentary on << Ipilimumab induced vasculitis >> by Padda A. et al., J Immunother Cancer. 2018;6:12. The authors diagnosed a small vessel vasculitis following treatment with anti-CTLA-4 (ipilimumab) for a resected stage III B/C melanoma. We report a similar case of acral vasculitis occurring with a combination of anti-CTLA-4 (tremelimumab) and anti-PD-L1 (durvalumab) prescribed for the management of a metastatic urothelial bladder cancer. In contrast to Padda A. et al., we observed a significant improvement with oral corticosteroids.
引用
收藏
页数:3
相关论文
共 5 条
[1]   Vasculitis associated with immune checkpoint inhibitors-a systematic review [J].
Daxini, Anisha ;
Cronin, Keri ;
Sreih, Antoine G. .
CLINICAL RHEUMATOLOGY, 2018, 37 (09) :2579-2584
[2]   Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade [J].
Gambichler, Thilo ;
Strutzmann, Stefanie ;
Tannapfel, Andrea ;
Susok, Laura .
BMC CANCER, 2017, 17
[3]   Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy [J].
Le Burel, Sebastien ;
Champiat, Stephane ;
Routier, Emilie ;
Aspeslagh, Sandrine ;
Albiges, Laurence ;
Szwebel, Tali-Anne ;
Michot, Jean-Marie ;
Chretien, Pascale ;
Mariette, Xavier ;
Voisin, Anne-Laure ;
Lambotte, Olivier .
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (03) :468-470
[4]   Ipilimumab induced digital vasculitis [J].
Padda, Amrita ;
Schiopu, Elena ;
Sovich, Justin ;
Ma, Vincent ;
Alva, Ajjai ;
Fecher, Leslie .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[5]  
Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMra1703481, 10.1056/NEJMc1801663]